METTL3 inhibitors disclosed by Storm Therapeutics scientists, compounds 6a − e (IC50 < 10 nM), compounds 7a-g and 8a-c (IC50 = 6.1 nM), as well as compounds 9a − d (IC50 < 6.3 nM) also inhibited the proliferation of the ovarian adenocarcinoma cell line Caov-3 and the AML cell line MOLM-13 or Kasumi-1 (Fig. 6a) [385]. This evidence concerns the gene METTL3 and acute myeloid leukemia.